Your session is about to expire
← Back to Search
Finerenone for Kidney Transplant Recipients
Study Summary
This trial will study the safety and effectiveness of a drug, finerenone, in 150 kidney transplant patients. It will also include two additional studies to further understand the effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the Drug and Food Administration sanctioned Finerenone?
"Given its Phase 2 classification, our team assigned Finerenone a score of 2 for safety. There is some evidence that it can be safely administrated however no data exists yet to confirm efficacy."
What are the objectives of this experiment in medical science?
"According to information from the trial's sponsor, Bayer Pharmaceuticals, the primary outcome measured over a 3-month period upon study initiation will be the overall feasibility of recruiting participants for kidney biopsies. Secondary outcomes that are being assessed include: risk of discontinuation associated with finerenone use, general safety levels when taking this drug, and adverse events related to hyperkalemia which necessitate acute care (i.e., hospitalization or emergency room visits)."
Are there still opportunities for volunteers to take part in the research?
"Per the information on clinicaltrials.gov, this medical trial is not currently enrolling participants. The initial posting was made on November 1st 2023 and it was last updated September 25th in the same year. Although this study isn't accepting volunteers presently, there are 43 other trials actively searching for participation."
Share this study with friends
Copy Link
Messenger